Abstract
The article presents a critical analysis of antibiotic usage tactics in the treatment of patients with COVID-19 existing in Russian and foreign healthcare, and discusses the possible causes of unjustified antibiotic aggression in this category of patients. The potential negative consequences of the widespread use of antibiotics in patients carrying a new coronavirus infection are analyzed: life-threatening cardiotoxicity in patients with the simultaneous administration of such a «popular» candidate etiologic therapy as a combination of azithromycin and hydroxychloroquine, the potential development of other serious adverse drug reactions (in particular, the development of an antibiotic-associated pseudomembranous colitis, etc.), the expected dramatic increase in the secondary drug resistance of potentially pathogenic microorganisms to widely and often prescribed antibiotics.
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
-
1.
Zhou F., Yu T., Du R., Fan G., Liu Y., Liuet Z., et al. Clinical course, and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;28:395(10229):1054-1062.
DOI: 10.1016/S0140-6736(20)30566-3
-
2.
Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-848.
DOI: 10.1007/s00134-020-05991-x
-
3.
Ahmed S., Jafri L., Hoodbhoy Z., Siddiqui I. Prognostic value of serum procalcitonin in COVID-19 patients: a systematic review. 2021;25(1):77-84.
DOI: 10.5005/jpjournals-10071-23706
-
4.
COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. NICE guideline. Published: 1 May 2020. Available at: www.nice.org.uk/guidance/ng173. Accessed March, 2021.
-
5.
Borges do Nascimento I.J., Cacic N., Abdulazeem H.M., Caspar von Groote T., Jayarajah U., Weerasekaraet I., et al. Novel Coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med. 2020;9:941.
DOI: 10.3390/jcm9040941
-
6.
Ebell M.H., Chupp H., Cai X., Bentivegna M., Kearney M. Accuracy of signs and symptoms for the diagnosis of community-acquired pneumonia: a meta-analysis. Acad Emerg Med. 2020;27:541-553.
DOI: 10.1111/acem.13965
-
7.
Yap F.H.Y., Gomersall C.D., Fung K.S.C., Ho P.-L., Ho O.-M., Lam P.K.N., et al. Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis. 2004;39(4):511516.
DOI: 10.1086/422641
-
8.
So L.K., Lau A.C., Yam L.Y., Cheung T.M., Poon E., Yung R.W., Yuen K.Y. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 2003;361(9369):1615-1617.
DOI: 10.1016/s01406736(03)13265-5
-
9.
Ho W.; Hong Kong Hospital Authority Working Group on SARS, Central Committee of Infection Control. Guideline on management of severe acute respiratory syndrome (SARS). Lancet. 2003;361(9366):1313-1315.
DOI: 10.1016/s0140-6736(03)13085-1
-
10.
Smucny J.J., Becker L.A., Glazier R.H., McIsaac W. Are antibiotics effective treatment for acute bronchitis? A metaanalysis. J Fam Pract. 1998;47:453-460. PMID: 9866671
-
11.
Hueston W.J. Antibiotics: neither cost effective nor 'cough' effective. J Fam Pract. 1997;44:261-265. PMID: 9071245
-
12.
Munster V.J., Koopmans M., van Doremalen N., van Riel D., de Wit E. A novel coronavirus emerging in China – key questions for impact assessment. N Engl J Med. 2020;382(8):692-694.
DOI: 10.1056/NEJMp2000929
-
13.
Lupia T., Scabini S., Pinna S.M., Di Perri G., De Rosa F.G., Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: a new challenge. J Glob Antimicrob Resist. 2020;21:22-27.
DOI: 10.1016/j.jgar.2020.02.021
-
14.
Synopalnikov A.I. Definition, classification and epidemiology of community-acquired pneumonia. In book: Clinical guidelines. Community-acquired pneumonia in adults. Eds. Chuchalin A.G., Synopalnikov A.I. M.: Atmosfera; 2005. P. 7-14. Russian.
-
15.
Chuchalin A.G., Sinopalnikov A.I., Stratchounski L.S., Kozlov R.S., Rachina S.A., Yakovlev S.V. Communityacquired pneumonia in adults: guidelines on diagnosis, treatment and prophylaxis. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2006;8(1):54-86. Russian.
-
16.
Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 10 (08.02.2021). Available at: www.minzdrav.gov.ru. Accessed February, 2021. Russian.
-
17.
Zaitsev A.A., Chernov S.A., Stets V.V., Patsenko M.B., Kudriashov O.I., Chernetsov V.A., Kriukov E.V. Algorithms for the management of patients with a new coronavirus COVID-19 infection in a hospital. Guidelines. Consilium Medicum. 2020;22(11):91-97. Russian.
DOI: 10.26442/20751753.2020.11.200520
-
18.
Gao Z., Xu Y., Sun C., Wang X., Guo Y., Qiu S., Ma K. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):1216.
DOI: 10.1016/j.jmii.2020.05.001
-
19.
Lai C.-C., Liu Y.H., Wang C.-Y., Wang Y.-H., Hsueh S.-C., Yen M.-Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53:404-412.
DOI: 10.1016/j.jmii.2020.02.012
-
20.
Menni C., Valdes A., Freydin M.B., Ganesh S., El-Sayed Moustafa J.S., Visconti A., et al. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection. medRxiv 2020.04.05.20048421.
DOI: 10.1101/2020.04.05.20048421
-
21.
Li Y., Wang J., Wang C., Yang Q., Xu Y., Xu J., et al. Characteristics of respiratory virus infection during the outbreak of 2019 novel coronavirus in Beijing. Int J Infect Dis. 2020;96:266-269.
DOI: 10.1016/j.ijid.2020.05.008
-
22.
Zhou F., Yu T., Du R., Fan G., Liu Y., Liuet Z., et al. Clinical ciurse and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
DOI: 10.1016/S01406736(20)30566-3
-
23.
Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of martality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846-848.
DOI: 10.1007/s00134-020-05991-x
-
24.
Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45-e67.
DOI: 10.1164/rccm.201908-1581ST
-
25.
Rule J.A., Hynan L.S., Attar N., Sanders C., Korzun W.J., Lee W.M., et al. Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure. PLoS One. 2015;10(9):e0138566.
DOI: 10.1371/journal.pone.0138566
-
26.
Kucirka L.M., Lauer S.A., Laeyendecker O., Boon D., Lessleret J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARSCoV-2 tests by time since exposure. Ann Intern Med. 2020;173:262-267.
DOI: 10.7326/M20-1495
-
27.
Fang Y., Zhang H., Xie J., Lin M., Ying L., Pang P., Ji W. Sensitivity of chest CT for COVID-19: comparison to RTPCR. Radiology. 2020;296:E115-E117.
DOI: 10.1148/radiol.2020200432
-
28.
Blažić I., Brkljačić B., Frija G. The use of imaging in COVID-19-results of a global survey by the International Society of Radiology. Eur Radiol. 2021;31:1185-1193.
DOI: 10.1007/s00330-020-07252-3
-
29.
Thoracic Imaging in COVID-19 infection. Guidance for the reporting radiologist British Society Thoracic Imaging. Version 1. 2020. Available at: www.bsti.org.uk. Accessed March, 2021.
-
30.
Duzgun S.A., Durhan G., Demirkazik F.B., Akpinar M.G., Ariyurek O.M. COVID-19 pneumonia: the great radiological mimicker. Insights Imaging. 2020;11:118.
DOI: 10.1186/s13244-020-00933-z
-
31.
Caruso D., Zerunian M., Polici M., Pucciarelli F., Polidori T., Rucci C., et al. Chest CT features of COVID-19 in Rome, Italy. Radiology. 2020;296:E79-E85.
DOI: 10.1148/radiol.2020201237
-
32.
Simpson S., Kay F.U., Abbara S., Bhalla S., Chung J.H., Chunget M., et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. J Thorac Imaging. 2020;35(4):219-227.
DOI: 10.1097/RTI.0000000000000524
-
33.
Gupta R.K., George R., Nguyen-Van-Tam J.S. Bacterial pneumonia and pandemic influenza planning. Emerg Infect Dis. 2008;14:1187-1192.
DOI: 10.3201/eid1408.070751
-
34.
Morris D.E., Cleary D.W., Clakke S.C. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017;8:1041.
DOI: 10.3389/fmicb.2017.01041
-
35.
Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198:962-970.
DOI: 10.1086/591708
-
36.
Zambon M.C. The pathogenesis of influenza in humans. Rev Med Virol. 2001;11:227-241.
DOI: 10.1002/rmv.319
-
37.
Klein E.Y., Monteforte B., Gupta A., Jiang W., May L., Hsieh Y.-H., Dugas A. The frequency of influenza and bacterial coinfection: a systematic review and metaanalysis. Influenza Other Respir Viruses. 2016;10:394403.
DOI: 10.1111/irv.12398
-
38.
Centers for Disease Control and Prevention. Bacterial coinfection in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) – United States, May-August 2009. Morb Mortal Wkly Rep. 2009;58:1071-1074. PMID: 19798021
-
39.
Gill J.R., Sheng Z.M., Ely S.F., Guinee D.G., Beasley M.B., Suh J., et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med. 2010;134:235-243.
DOI: 10.1043/15432165-134.2.235
-
40.
Weinberger D.M., Simonsen .L, Jordan R., Steiner C., Miller M., Viboudet C., et al. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis. 2012;205:458-465.
DOI: 10.1093/infdis/jir749
-
41.
Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and metaanalysis. J Infect. 2020;81:266-275.
DOI: 10.1016/j.jinf.2020.05.046
-
42.
Garcia-Vidal C., Sanjuan G., Moreno-García E., Puerta-Alcalde P., Garcia-Pouton N., Chumbitaet M., et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83-88.
DOI: 10.1016/j.cmi.2020.07.041
-
43.
Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71:2459-2468.
DOI: 10.1093/cid/ciaa530
-
44.
Hughes S., Troise O., Donaldson H., Mughal N., Moore L.S.P. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395-1399.
DOI: 10.1016/j.cmi.2020.06.025
-
45.
Zhou F., Yu T., Du R., Fan G., Liu Y., Liuet Z., al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
DOI: 10.1016/S0140-6736(20)30566-3
-
46.
Rawson T.M., Wilson R.C., Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021;27(1):9-11.
DOI: 10.1016/j.cmi.2020.09.025
-
47.
Gautret P., Lagier J.-C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.
DOI: 10.1016/j.ijantimicag.2020.105949
-
48.
RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605-612.
DOI: 10.1016/S01406736(21)00149-5
-
49.
WHO Solidarity Trial Consortium; Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.-P., Sathiyamoorthy V., Abdool Karim Q. Repurposed antiviral drugs for Covid-19 interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497-511.
DOI: 10.1056/NEJMoa2023184.
-
50.
RECOVERY Collaborative Group; Horby P., Mafham M., Linsell L., Bell J.L., Staplin N., Emberson J.R., et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030-2040.
DOI: 10.1056/NEJMoa2022926
-
51.
Molina J.M., Delaugerre C., Le Goff J. , Mela-Lima B., Ponscarme D., Goldwirt L., de Castro N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.
DOI: 10.1016/j.medmal.2020.03.006
-
52.
Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C.P., Veiga V.C., Avezum A., et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383:2041-2052.
DOI: 10.1056/NEJMoa2019014
-
53.
Fiolet T., Guihur A., Rebeaud M.E., Mulot M., PeifferSmadja N., Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):1927.
DOI: 10.1016/j.cmi.2020.08.022
-
54.
Tisdale J.E. In: Wiggins B.S., Sanoski C.A., Eds. Emergency cardiovascular pharmacotherapy. A point of care guide. 2012: pp. 23, 38.
-
55.
Owens R.C. Jr. QT Prolongation with antimicrobial agents understanding the significance. Drugs. 2004;64:10911124.
DOI: 10.2165/00003495-200464100-00005
-
56.
Kim M.H., Berkowitz C., Trohman R.G. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol. 2005;28:12211222.
DOI: 10.1111/j.1540-8159.2005.50146.x
-
57.
Naksuk N., Lazar S., Peeraphatdit T.B. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020;9:215-221.
DOI: 10.1177/2048872620922784
-
58.
Mercuro N.J., Yen C.F., Shim D.J., Maher T.R., McCoy C.M., Zimetbaum P.J., Gold H.S. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036-1041.
DOI: 10.1001/jamacardio.2020.1834
-
59.
Brown K.A., Khanafer N., Daneman N., Fisman D.N. Metaanalysis of antibiotics and the risk of communityassociated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57:2326-2332.
DOI: 10.1128/AAC.02176-12
-
60.
Sandhu A., Tillotson G., Polistico J., Salimnia H., Cranis M., Moshos J., et al. Clostridiodes difficile in COVID-19 patients, Detroit, Michigan, USA, March–April 2020. Emerg Infect Dis. 2020;26:2272-2274.
DOI: 10.3201/eid2609.202126
-
61.
Lewandowski K., Rosołowski M., Kaniewska M., Kucha P., Meler A., Wierzba W., Rydzewska G. Clostridioides difficile infection in coronavirus disease 2019 (COVID-19): an underestimated problem? Pol Arch Intern Med 2021;131:121-127.
DOI: 10.20452/pamw.15715
-
62.
Murray A.K. The novel coronavirus COVID-19 outbreak: global implications for antimicrobial resistance. Front Microbiol. 2020;11:1020.
DOI: 10.3389/fmicb.2020.01020
-
63.
ISARIC. International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC); 2020. Available at: https://isaric.tghn.org/. Accessed March, 2021.
-
64.
Langford B.J., So M., Raybardhan S., Leung V., Soucy J.-P., Westwood D., et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;1:18.
DOI: 10.1016/j.cmi.2020.12.018
-
65.
George P.M., Barratt S.L., Condliffe R., Desai S.R., Devaraj A., Forrest I., et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75:10091016.
DOI: 10.1136/thoraxjnl-2020-215314
-
66.
Zhao Y.-M., Shang Y.-M., Song W.-B., Li Q.-Q., Xie H., Xu Q.-F., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
DOI: 10.1016/j.eclinm.2020.100463
-
67.
Sieswerda E., de Boer M.G.J., Bonten M.M.J., Boersma W.G., Jonkers R.E., Aleva R.M., et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence-based guideline. Clin Microbiol Infect. 2021;27(1):61-66.
DOI: 10.1016/j.cmi.2020.09.041